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ABSTRACT: Background: It is estimated that hypertensive 
disorders in pregnancy affect 6-8% of pregnant women in the 
United States, and they are considered one of the main factors 
of maternal mortality. In Brazil, according to DATASUS, if 
consider the categories of O13 to O16 ICD-10, hypertensive 
disorders accounted for about 20.22% of maternal deaths in the 
period of 2004 to 2014. Objectives: This review aims to present 
the most current treatments for the management of hypertensive 
disorders during pregnancy. Methodology: The Medline/Pubmed, 
LILACS/SciELO, Cochrane library and Scopus databases were 
consulted, looking for national and international articles published 
between 2006 and 2016, in English and Portuguese, as well as 
consensuses set by the World Health Organization and DATASUS 
government statistics. Results: The recommended managements 
to prevent preeclampsia (PE) were calcium supplementation for 
pregnants with low dietetic ingestion and the administration of 
low doses of aspirin. In front of PE, if it happens on term, the 
procedure is to induce the delivery, but if it occurs pre-term, is to 
monitore, administrate magnesium sulfate (MS), antihypertensive 
and corticoid. In case of eclampsia, the MS is very effective to 
reduce eclamptic seizures. The drugs used in treatment of severe 
chronic hypertension (HY) is methyldopa in association or not, 
with nifedipine or hydralazine. The acute HY is treated with 
first line drugs, nifedipine and hydralazine, and alternatively 
with sodium nitroprusside. Conclusion: The main worldwide 
protocols basically follow the same orientation, only changing 
specific details of conduct according to each country’s health 
system resources. The control of maternal blood pressure shows 
satisfactory results for both, the mother and the fetus, since it 
reduces the risk of PE and eclampsia. The definitive treatment 
for PE and eclampsia is the induction of delivery, because they 
have no cure, only therapeutic measures to control. 
Keywords: Eclampsia; Preeclampsia; Pregnancy-induced 
hypertension/therapy; Pregnancy; Therapeutics.
RESUMO: Introdução: Estima-se que os distúrbios hipertensivos 
na gravidez afetam 6-8% das gestantes nos Estados Unidos e são 
considerados um dos principais fatores de mortalidade materna. 
No Brasil, de acordo com o DATASUS, se considerarmos as 
categorias O13 a O16 do CID-10, os distúrbios hipertensivos 
representaram cerca de 20,22% das mortes maternas no período 
de 2004 a 2014. Objetivos: O objetivo da revisão é demonstrar 
os tratamentos mais atuais para o tratamento de distúrbios 
hipertensivos durante a gravidez. Métodos: Foram consultadas as 
bases de dados Medline/Pubmed, LILACS/SciELO, Cochrane e 
Scopus, procurando artigos nacionais e internacionais publicados 
entre 2006 e 2016, em inglês e português, bem como os consensos 
estabelecidos pela Organização Mundial da Saúde e as estatísticas 
do DATASUS. Resultados: As medidas recomendadas para 
prevenir a pré-eclâmpsia (PE) foram a suplementação de cálcio 
para gestantes com baixa ingestão dietética e a administração 
de baixas doses de aspirina. Na PE, se acontecer no termo, o 
tratamento é induzir o parto, mas se ocorrer pré-termo, é monitorar, 
administrar sulfato de magnésio (SM), anti-hipertensivos e 
corticóide. Em caso de eclâmpsia, a SM é muito eficaz para reduzir 
as convulsões eclâmpticas. Os fármacos utilizados no tratamento 
da hipertensão crônica grave são metildopa em associação ou não, 
com nifedipina ou hidralazina. A crise hipertensiva aguda é tratada 
com fármacos de primeira linha, como nifedipina e hidralazina, 
e alternativamente com nitroprussiato de sódio. Conclusão: Os 
principais protocolos mundiais seguem basicamente a mesma 
orientação, mudando apenas detalhes específicos de conduta 
de acordo com os recursos do sistema de saúde de cada país. 
O controle da pressão arterial materna apresenta resultados 
satisfatórios para o binômio materno-fetal, pois reduz o risco de 
PE e eclâmpsia. O tratamento definitivo para PE e eclâmpsia é 
a indução de parto, sendo utilizado apenas medidas terapêuticas 
para controle, já que não têm cura.
Descritores: Eclâmpsia; Preeclâmpsia; Hipertensão induzida pela 
gravidez/terapia; Gravidez; Terapêutica.
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INTRODUCTION
It is estimated that hypertensive disorders in pregnancy affect 6-8% of pregnant women in 
the United States9. In Brazil, according to DATASUS, 
hypertensive disorders account for about 20.22% of 
maternal deaths in the period of 2004 to 2014. 
The hypertensive disorders of pregnancy (HDP) 
have a dichotomous frequency: young women in their first 
pregnancy and in older multiparous women.
Morphological and functional changes in the 
body of pregnant women with HDP are caused by a large 
increase in peripheral vascular resistance, hyperreactivity 
to vasoconstrictor, endothelial dysfunction, vasospasm, 
and activation of coagulation mechanisms help in raising 
the pressure3,9. Placenta, kidney, liver and brain have their 
functions depressed by up to 60%, which proves that the 
HDP are severe, therefore intensify the risks of placental 
abruption, prematurity, low weight at birth, and maternal 
and fetal death9.
HPD is defined as systolic blood pressure (SBP) 
>140 mmHg and diastolic blood pressure (DBP) >90 
mmHg5. Pre-eclampsia is defined as hypertension 
associated with proteinuria. Proteinuria is defined as 
the excretion of 300 mg or more of proteins in 24 h or 
proteinuria with a concentration of 300 mg / L or more of 
proteins (≥ 1 + dipstick) in two different urine samples with 
a range of at least 4 to 6 h3. PE can manifest like a presence 
the swellings in face, hands, lower limbs or generalized 
swelling. The diagnosis is usually made after the 20th 
week of gestation, although early cases may occur in the 
hydatidiform mole or fetal hydrops.
Severe preeclampsia is defined as systolic blood 
pressure ≥ 160 mmHg and/or diastolic ≥ 110 mmHg 
associated with proteinuria; hypertension associated with 
severe proteinuria (above 2.0 g in 24 h); hypertension 
associated with multiple organ involvement (pulmonary 
edema and oliguria - <500 mL / day); And hypertension 
associated with persistent symptoms (visual, cerebral 
and persistent epigastric or right upper quadrant pain) or 
altered laboratory tests (platelet count - <100,000 per μL 
and hepatic enzymes)3.
Eclampsia is defined by expression of one or more 
seizures or coma in pregnant women with gestational 
hypertension or preeclampsia, in the absence of neurological 
diseases and HELLP syndrome, which consists in the 
presence of thrombocytopenia, microangiopathichemolysis 
and liver dysfunction in pregnancy toxemia. It can occur 
during pregnancy, labor and immediately after delivery.
In view of the risks exposed and risk factors for 
HDP, was determined as objective to present the main 
and most current treatments in clinical practice for the 
management of hypertensive disorders during pregnancy; 
in alerting health professionals for early diagnosis of 
different clinical forms and thus reduce damage to mothers 
and concepts.
Table 1. Diagnostic Criteria for Pregnancy-Associated Hypertension
Diagnostic Criteria for Pregnancy-Associated Hypertension
Gestational Hypertension
- Blood Pressure (BP) ≥ 140/90 mmHg for first time during pregnancy
- No proteinuria
- BP returns to normal < 12 weeks postpartum 
- Final diagnosis made only postpartum
Preeclampsia
Minimum Criteria
  - BP ≥ 140/90 mmHg after 20 weeks gestation
  - Proteinuria ≥ 300mg/24hours or ≥ 1+ dipstick
Increased certainty of preeclampsia
   - BP ≥ 160/110 mmHg
   - Proteinuria 2g/24hours or ≥ 2+ dipsticks
   - Serum creatinine > 1,2mg/dL unless known to be previously elevated
   - Platelets < 100,000/mm
   - Microangiopathic hemolysis (Increased LDH)
   - Elevated ALT or AST
   - Persistente headache or other cerebral or visual disturbance
   - Persistent epigastric pain
Eclampsia
- Preeclampsia + convulsion
- Seizures (generalized and may appear before, during or after labor) that  cannot be attributed to other causes on woman with 
preeclampsia
Preeclampsia Superimposed on Chronic Hypertension
- New-onset proteinuria ≥ 300mg/24hrs in hypertensive women but no proteinuria before 20 weeks gestation
- A sudden increase in proteinuria or BP or platelet count <100,000mm in women with hypertension and proteinuria before 20 weeks gestation
Chronic Hypertension
- BP ≥ 140/90 mmHg before pregnancy or diagnosed before 20 weeks gestation (not attributable to gestational trophoblastic disease) or 
- Hypertension first diagnosed after 20 weeks gestation and persistent after 12 weeks postpartum
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METHODS 
This is a review of the bibliography, where the 
following databases were consulted: Medline/Pubmed, 
LILACS/SciELO, Cochrane library and Scopus. Searching 
for national and international articles published between 
2006 and 2016, in English, Portuguese and Spanish 
(languages understood by the review authors) as well as 
consensuses set by the World Health Organization (WHO) 
and DATASUS government statistics. Were selected 8 
papers to make this review.The articles that were selected 
covered the topics of: definition, diagnosis, treatment and 
management. The descriptors used were “eclampsia”, 
“preeclampsia” “pregnancy-induced hypertension”, 
“treatment” and “pregnancy”.
RESULTS
Prevention
After all, it was obtained that the first step is 
prevention, since it is able to reach a larger number 
of pregnant women andit is more cost-effective. It 
basically consists in: Family history assessment, prior 
health assessment of the pregnant woman (Knowledge 
of basal levels in the pre conception to better pregnancy 
monitoring), identify pregnant women’s risk group (chronic 
hypertension, diabetes, obesity, nephropathy, neurological 
disorders, previous case report of preeclampsia and 
eclampsia), attentive evaluation in prenatal risk groups. 
Recommendations for risk groups to reduce vigorous 
activities, low sodium and low protein diet, awareness and 
guidance pregnant women to watch for signs installation 
of hypertensive disorders of pregnancy are essential either 
for prevent HDP. In developed countries there are already 
prevention campaigns to this problem. For now consider 
that the efficient and valuable way to pre-eclampsia and 
prevent eclampsia9.
The pioneer drug in the prevention and PE 
installation reversal is the Calcium Supplementation 
for pregnant women. It appears to be effective that was 
observed as an inverse ratio between calcium intake and 
hypertensive disorders in pregnancy. In a study of recent 
research, daily supplementation with 2000 mg calcium 
for pregnant woman produces a reduction in the risk of 
developing preeclampsia about 66.70% and 40.90% of the 
risk of a premature birth. The Dietary Intake references 
indicate appropriate recommendations for calcium for 
pregnant women: Between 14 -18 years 1300mg Ca² / day 
and between 19-50 years old 1000mg Ca² / day (Table 2).
Table 2. Calcium intake in pregnancy women to prevent 
hypertensive disorders of  pregnancy
Age Dietary Intake
14 -18 years 1300mg Ca² / day
19-50 years 1000mg Ca² / day
Treatment of Preeclampsia
Regarding the treatment of preeclampsia, there are 
two possibilities: expectant management with rigorous 
monitoring of disease evolution according gestation age, 
fetal vitality and severity of the disease or resolution of 
pregnancy to cure the disease3.
Expectant management may be the first conduct 
in pregnant women with gestational age of less than 34 
weeks, always evaluating the risk of prolonged gestation11. 
It consists of high-risk prenatal counseling with laboratory 
evaluation of proteinuria, relative rest, weight control, 
follow-up with hemogram, liver and renal function, as well 
as assessment of fetal vitality5. The use of hypotensive drugs 
such as Pindolol and Methyldopa must be individualized 
for each case according to the evolution of the disease, 
since its use is not mandatory12. If there is no complication, 
theseactions should be taken until the 34th week when the 
resolution of gestations can be performed, but they should 
be delivered at term6. For those who gestational age is 
greater than 34 weeks, the delivery should be indicated, 
but the best way acting depends on fetal vitality. If there 
is no sign of fetal compromise, the gestations can usually 
go through to the end.
Treatment of Severe Preeclampsia
Two different paths could be adopted, which are 
based on gestational age. Thus, before 23 or after 34 weeks, 
delivery is the treatment of choice11. After 34 weeks if 
uncontrolled maternal hypertension, increasing maternal 
organ dysfunction or fetal distress are absent and can be 
monitored, between 34 and 37 weeks of gestation, a policy 
of expectant management may be recommended2. 
When the concept is between 23 and 34 weeks, 
the initial procedure to be performed is to administrate 
Hydralazine 5mg EV every 15 minutes until the control 
of the condition or until reaching 20mg. If the goal is not 
achieved, a second drug may be used, nifedipine 10mg, 
which can be repeated after 30 minutes. If still the clinical 
condition remains, consider the use of sodium nitroprusside 
0.2 - 5 mcg /kg /min (Figure 1), which should only be used 
in these refractory cases, since its degradation in cyanide 
is toxic to the fetus.
In association of BP control procedure, magnesium 
sulfate should be used to prevent evolution to eclampsia. 
Reminding that corticoid use is essential for fetus’s lung 
development when the delivery is before 34 weeks. If 
the symptoms remain unchanged or the patient develops 
eclampsia or HELLP syndrome, C-section is recommended. 
During all patient management, clinical and laboratorial 
monitoring of mother and fetal well-being is essential.
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Figure 1. Treatment of severe preeclampsia
Treatment of Eclampsia
The eclampsia’s management is administration of 
magnesium sulfate, ventilatory and hemodynamic support. 
After stabilization, immediate resolution of pregnancy is 
indicated. Zuspan’s scheme is preferred, despite a higher 
risk of intoxication, which consistsin a loading dose of 
magnesium sulfate 200mg /ml EV for 10-20min followed 
by a maintenance dosing of magnesium sulfate 10mg / ml 
EV in an infusion pump at a rate of 100ml/h.
CONCLUSION
Several studies look for an efficient method to 
reduce the incidence and severity of HDP, however, this 
methodology has not been found yet.In this way, we have 
the conclusion to our results that appropriate interventions 
in the prenatal collaborate to reduce complications and 
maternal deaths from hypertension.
So, it is essential greater investments in prevention 
and early diagnosis.
And the care of hypertensive pregnant patient 
should be done with rest and diet, being recommended 
drug treatment only when necessary.
As a future perspectives of study, in view of 
statistical relevance and complications that HDP can cause 
to the mother and the fetus,were suggested the initiative 
of a project to conduct a Systematic Review to assist in 
developing an effective prevention protocol and improved 
clinical management and also assess the impact on public 
management.
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